We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ready-To-Use Panels Fulfill CLIA’s Performance Specifications for Assay Verification

By LabMedica International staff writers
Posted on 12 Sep 2023
Print article
Image: AccuSet HIV Verification Panel is a 20-member validation panel of undiluted, naturally occurring plasma samples (Photo courtesy of LGC)
Image: AccuSet HIV Verification Panel is a 20-member validation panel of undiluted, naturally occurring plasma samples (Photo courtesy of LGC)

LGC Clinical Diagnostics (Middlesex, UK) - SeraCare (Milford, MA, USA) has launched its AccuSet HIV Verification Panels - ready-to-use panels designed to fulfill ISO and CLIA’s Performance Specifications for assay verification.

The AccuSet HIV Verification Panels are a great tool to help install a new HIV test method and perform assay verification, as well as help evaluate assay performance during development, performing assay validation, and troubleshoot test methods. These panels consist of naturally occurring plasma samples that perfectly mimic patient specimens on laboratory instrumentation. The panels include highly characterized mixed-titer samples that will allow users to efficiently onboard their new assays.

The company offers two HIV Verification Panels to provide labs with options for onboarding both molecular and serological HIV assays based on their specific verification requirements. With the choice of one or both verification panels, labs can tailor their selection to match specific verification protocols. The AccuSet HIV Verification Panels provide the tools labs need to easily meet CLIA’s performance specifications so that users can verify their test system and start reporting patient results.

Related Links:
LGC 
SeraCare 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more